Cargando…

Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases

BACKGROUND: Brain metastases (BM) are a frequent complication of advanced cancer and are characterized by a variety of neurological symptoms. Although the presence of neurological symptoms is included in the response assessment in patients with primary brain tumors, to the authors' knowledge li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steindl, Ariane, Yadavalli, Sarah, Gruber, Katharina‐Anna, Seiwald, Maria, Gatterbauer, Brigitte, Dieckmann, Karin, Frischer, Josa M., Klikovits, Thomas, Zöchbauer‐Müller, Sabine, Grisold, Anna, Hoda, Mir Ali Reza, Marosi, Christine, Widhalm, Georg, Preusser, Matthias, Berghoff, Anna Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540353/ https://www.ncbi.nlm.nih.gov/pubmed/32678971 http://dx.doi.org/10.1002/cncr.33085

Ejemplares similares

Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort
por: Steindl, Ariane, et al.
Publicado: (2019)

Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases
por: Starzer, Angelika M., et al.
Publicado: (2021)

Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
por: Wolff, Ladislaia, et al.
Publicado: (2023)

Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases
por: Furtner, Julia, et al.
Publicado: (2018)

Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases
por: Furtner, Julia, et al.
Publicado: (2017)

Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles
por: Steindl, Ariane, et al.
Publicado: (2021)

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
por: Berghoff, Anna S, et al.
Publicado: (2016)

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours
por: Mair, Maximilian J, et al.
Publicado: (2020)

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
por: Steindl, A., et al.
Publicado: (2021)

Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients
por: Cho, Anna, et al.
Publicado: (2020)

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center
por: Füreder, L. M., et al.
Publicado: (2018)

High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases
por: Leitner, Johannes, et al.
Publicado: (2018)

Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation
por: Steindl, Ariane, et al.
Publicado: (2020)

Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times
por: Berghoff, Anna Sophie, et al.
Publicado: (2013)

Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy
por: Cho, Anna, et al.
Publicado: (2020)

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma
por: Preusser, Matthias, et al.
Publicado: (2014)

New developments in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Anti-angiogenic therapies in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Targeted Therapies for Melanoma Brain Metastases
por: Berghoff, Anna S., et al.
Publicado: (2017)

LAG-3 expression in the inflammatory microenvironment of glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor
por: Cho, Anna, et al.
Publicado: (2021)

Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases
por: Bergen, E.S., et al.
Publicado: (2021)

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
por: Berghoff, A S, et al.
Publicado: (2012)

Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy—A retrospective cohort study
por: Gatterbauer, Brigitte, et al.
Publicado: (2020)

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
por: Bienkowski, Michal, et al.
Publicado: (2015)

Prognostic impact of genetic alterations and methylation classes in meningioma
por: Berghoff, Anna S., et al.
Publicado: (2022)

Susceptibility-weighted imaging at 7 T: Improved diagnosis of cerebral cavernous malformations and associated developmental venous anomalies()()
por: Frischer, Josa M., et al.
Publicado: (2012)

Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?
por: Berghoff, Anna S., et al.
Publicado: (2012)

Brain metastases from hepatopancreatobiliary malignancies
por: Bergen, Elisabeth S., et al.
Publicado: (2023)

Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma
por: Mair, Maximilian J., et al.
Publicado: (2020)

Management of malignant pleural mesothelioma—part 2: therapeutic approaches: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Hoda, Mir Alireza, et al.
Publicado: (2016)

SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES
por: Mercea, Petra Andreea, et al.
Publicado: (2019)

Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
por: Sinn, K., et al.
Publicado: (2022)

Corrigendum to ‘Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study’: [ESMO Open Volume 7, Issue 2, April 2022, 100466]
por: Sinn, K., et al.
Publicado: (2022)

Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2020)

Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2019)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
por: Bergen, Elisabeth Sophie, et al.
Publicado: (2021)

Controversies in oncology: surgery for small cell lung cancer? It’s time to rethink the case
por: Hoda, Mir Alireza, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sq3aoc9mg5v0cfebcqmcfr80o9